Therapeutic Asset Ratings
123 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Clofarabine
Leukemia
Memorial Sloan Kettering Cancer Center
P3
BB
(64)
Arsenic Trioxide
Leukemia
SDK Therapeutics, Inc.
P3
B
(63)
Azacitidine
Leukemia
Jacqueline Garcia, MD
P3
B
(63)
TACROLIMUS
Leukemia
National Cancer Institute (NCI)
P3
B
(63)
Equine Atg
Leukemia
Peking University People's Hospital
P2/3
B
(63)
Allopurinol
Leukemia
M.D. Anderson Cancer Center
P2
B
(62)
cc-5013
Leukemia
M.D. Anderson Cancer Center
P2
B
(62)
Cladribine
Leukemia
M.D. Anderson Cancer Center
P2
B
(62)
Rapamycin
Leukemia
Masonic Cancer Center, University of Minnesota
P2
B
(62)
Decitabine
Leukemia
Dana-Farber Cancer Institute
P2/3
B
(62)
Quizartinib
Leukemia
Daiichi Sankyo
P3
B
(60)
Venetoclax
Leukemia
Jacqueline Garcia, MD
P3
B
(60)
Monomethyl Fumarate
Leukemia
National Cancer Institute (NCI)
P3
B
(59)
Midostaurin
Leukemia
Richard Stone, MD
P3
B
(58)
Ibrutinib
Leukemia
Inhye Ahn
P2
B
(58)
Nelarabine
Leukemia
University of Chicago
P2
B
(58)
Palifermin
Leukemia
Memorial Sloan Kettering Cancer Center
P3
B
(57)
Chimeric Antigen Receptor Modified T Cells Infusion
Leukemia
Princess Maxima Center for Pediatric Oncology
P2
B
(56)
Gm-Csf
Leukemia
Medical College of Wisconsin
P2
B
(56)
Obinutuzumab
Leukemia
Molecular Partners AG
P2
B
(56)
HUMAN IMMUNOGLOBULINS
Leukemia
Monash University
P2/3
B
(56)
Vinorelbine
Leukemia
Memorial Sloan Kettering Cancer Center
P1/2
CCC
(55)
Hpc, Cord Blood
Leukemia
Memorial Sloan Kettering Cancer Center
P2
CCC
(54)
Recombinant Human Interleukin-2
Leukemia
Dana-Farber Cancer Institute
P2
CCC
(54)
Tucidinostat
Leukemia
The First Affiliated Hospital of Xiamen University
P2/3
CCC
(54)
Showing 26 to 50 of 123 assets
Previous
Page 2 of 5
Next
